CION Ameerpet
Treatment Explained · Reviewed by CION Oncologists · NABH Accredited
Do You Need Treatment After Surgery? Often, the Answer Is No
This is the question that dominates the weeks after an operation for endometrial cancer, and it deserves a direct answer. For a large group of women — early-stage, low-grade disease with no other risk features — the recommendation is nothing at all. Not watchful waiting, not a compromise: surgery alone is the standard of care, because the risk of recurrence is low enough that treating everybody would expose many women to lasting side effects to benefit very few. For other women, a short course of internal radiation. For a smaller group, more. This page explains how that decision is actually made and where your own view legitimately enters it.
- Decided on the final pathology — not the scan, and not before the operation
- Low risk means surgery alone — a large group, and it is the correct recommendation
- Intermediate risk usually means vault brachytherapy — a few outpatient sessions, not weeks of treatment
- Your own view counts — where the absolute benefit is small, that is a real conversation
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Seven Things That Decide It
No single finding determines the answer. The tumour board weighs these together, and a woman who knows all seven can follow the reasoning rather than receiving a conclusion.
- Stage. How far the cancer travelled, established from the specimen. See FIGO staging.
- Grade. How abnormal the cells look. Grade 3 shifts the assessment substantially. See endometrial cancer grades.
- Histological type. Serous, clear cell and carcinosarcoma are managed more intensively even at early stage. See Type 2 endometrial cancer.
- Depth of invasion into the muscle wall. Less than half, or half or more — the strongest predictor within stage I of whether cells have reached the nodes.
- Lymphovascular space invasion. Tumour cells inside the small vessels of the uterine wall. Substantial LVSI raises the risk category on its own and is the commonest reason an apparently low-risk woman is offered treatment.
- Lymph node status. What the sampled nodes showed. See sentinel node biopsy.
- Molecular group. POLE-mutated, mismatch repair deficient, p53-abnormal, or no specific profile. Can move the answer in either direction. See MMR and MSI testing.
If you have been given a recommendation without being told all seven, they are on a report that already exists and it is entirely reasonable to ask for them.
Did You Know? The most important thing to understand about this decision is that it is made after surgery, on the specimen, and that this is deliberate rather than a delay. Imaging cannot detect microscopic disease in normal-sized lymph nodes, cannot measure depth of invasion precisely, and cannot assess lymphovascular space invasion at all — and that last finding alone is one of the commonest reasons a woman expecting no further treatment is offered radiation. Grades and stages are also revised in both directions once the whole uterus is examined. Any plan discussed before the operation is genuinely provisional, and a team that says so is being accurate rather than evasive. Sources: ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; PORTEC randomised trials of adjuvant radiotherapy in endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; FIGO staging system, 2023 revision.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The Risk Groups, and What Each Is Offered
Broad categories rather than rigid rules — individual cases sit near boundaries, which is where discussion matters most.
| Risk group | Broadly who this is | What is usually recommended |
|---|---|---|
| Low | Stage I, endometrioid, Grade 1 or 2, invasion less than half the muscle wall, no substantial LVSI. | Nothing. Surgery alone is standard. Treating this group would expose many women to side effects to benefit very few. |
| Intermediate | Stage I with deeper invasion, or Grade 3 with shallow invasion — one adverse feature rather than several. | Vaginal vault brachytherapy: a few outpatient sessions targeting the site where recurrence usually appears. See vault brachytherapy. |
| High-intermediate | Several adverse features together, or substantial lymphovascular space invasion, or older age combined with other factors. | Vault brachytherapy or pelvic radiation, depending on the balance. This is the group where the discussion is genuinely finely balanced. |
| High | Stage II or III, deep invasion with Grade 3, node involvement, or an aggressive histological type. | Pelvic radiation, chemotherapy, or both. See pelvic radiation and chemotherapy. |
| Advanced or metastatic | Stage IVB, or residual disease after surgery. | Systemic treatment as the backbone. See treating advanced disease. |
Where you sit is a judgement, not a lookup. A woman with two mild adverse features and a woman with one severe one can land in the same category by different routes, and the right answer for each may differ. This is precisely why the decision belongs to a tumour board rather than to a table — and why it is reasonable to ask which features put you where.
Told You Need Radiation and Not Sure Why?
There is a specific reason, and it is on your pathology report. Bring it and we will find it.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
For a Large Group, Surgery Alone Is the Right Answer
Knowing whether you are in that group is worth an appointment — as is knowing why, if you are not.
What to ask, and what to weigh
How to Have This Conversation Well
Where the absolute benefit of adding treatment is a few percentage points, your own judgement is a legitimate part of the decision rather than an obstacle to it.
Ask for absolute numbers, not relative ones
A treatment described as reducing recurrence risk "by half" sounds compelling and tells you almost nothing on its own. Halving a risk from 4 per cent to 2 per cent is a very different proposition from halving it from 30 per cent to 15 per cent, though both are a fifty per cent reduction. Ask what your risk of recurrence is with treatment and without it, expressed as absolute figures. Any oncologist who has recommended treatment can give you both numbers, and having them changes the conversation from deference to genuine choice.
Ask what the treatment is aimed at
Vault brachytherapy reduces recurrence at the top of the vagina. Pelvic radiation additionally reduces recurrence in the pelvic lymph node regions. Chemotherapy addresses the risk of disease outside the treated area entirely. These are different risks, and knowing which one your treatment targets clarifies why a particular option has been chosen — and why, for instance, adding pelvic radiation would not help if the concern is distant spread. It also makes it easier to understand what declining a component would and would not forgo.
Ask about the side effects that last
Short-term effects during treatment matter less to most women than what persists. Vault brachytherapy carries vaginal dryness and narrowing, both manageable with dilator use. Pelvic radiation adds a meaningful risk of lasting bowel and bladder changes and of leg lymphoedema, particularly where nodes have been removed. Chemotherapy can leave fatigue and sometimes nerve symptoms. These are the trade-offs against a few percentage points of recurrence risk, and they deserve equal airtime. See radiation side effects.
Ask whether molecular testing is complete
This can change the recommendation in either direction and is sometimes incomplete when the adjuvant discussion happens. A POLE-mutated tumour behaves very favourably even at Grade 3, and European guidance supports giving less treatment rather than more. A p53-abnormal tumour is managed as high risk regardless of how modest the stage appears. Both results come from tissue already removed at surgery. If POLE sequencing in particular has not been done, it is worth asking whether it can be before the plan is finalised.
Say what matters to you
Two women with identical pathology can reasonably reach different decisions, and this is not a failure of medicine. One may want everything that might help and accept the side effects readily. Another, weighing a small absolute gain against several weeks of treatment and lasting effects on bowel, bladder and sexual function, may decline clearly and reasonably. Age, other health conditions, caring responsibilities and what you want your next year to look like are all legitimate inputs. A good discussion invites them rather than treating them as noise.
Ask for time, and a second opinion if you want one
This decision is rarely urgent in the way surgery was. There is usually room to take a week, read the report properly, discuss it with family, and seek another view. Asking for that is not obstruction and no reasonable team will treat it as such. If you do seek a second opinion, bring the full pathology report and the molecular results rather than a summary — the whole point is that the decision turns on details. See when a second opinion is worth it.
Want the Recommendation Reviewed?
The full pathology, the molecular results, and whether the plan matches current guidance for your risk group. The opinion is free.
Four Situations Worth Questioning
None of these is necessarily wrong. All of them are worth a specific question.
Radiation offered for what you were told was low risk
Something moved you out of that category, and it is usually substantial lymphovascular space invasion or a deeper invasion than expected — both findings that only appear on the final pathology. Ask which feature it was. If the answer is not clear, or if the pathology was borderline, that is a reasonable reason to seek a second reading.
Chemotherapy offered for early low-grade disease
Uncommon and worth understanding. Chemotherapy is not routine for early-stage endometrioid cancer, so its recommendation usually reflects an aggressive histological type identified on the final specimen, node involvement, or a p53-abnormal molecular result. Any of those is a sound reason; none of them should be left unstated.
Pelvic radiation where brachytherapy might do
For intermediate-risk disease, randomised evidence showed vault brachytherapy to be as effective as pelvic radiation at preventing vaginal recurrence, with significantly less bowel toxicity. Where your case sits near that boundary, it is fair to ask which risk features justify treating the wider pelvis rather than the vault alone — the difference in lasting side effects is substantial.
A plan made without a tumour board
The adjuvant decision weighs surgical, radiation and medical oncology considerations together, and a recommendation assembled by one specialty in isolation tends to reflect that specialty's tools. Asking whether your case has been discussed by the full board is a reasonable question with a factual answer, and in higher-risk cases it genuinely affects the quality of the plan.
Why This Decision Belongs to a Board, Not a Table
Seven findings, three specialties, and a genuine trade-off. That is a discussion, not a lookup.
Tumour board for every diagnosis
Slides reviewed, not just the summary line
MMR / MSI testing as standard
Vault brachytherapy on site
Image-guided pelvic radiation
Decisions for healing, not billing
Take The Next Step
Ask for the Absolute Numbers
Your risk with treatment and without it. Both exist, and having them turns a recommendation into a decision.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Treatment After Surgery — Frequently Asked Questions
Will I need treatment after surgery for endometrial cancer?
For a large group of women, no. If the final pathology shows stage I endometrioid cancer, Grade 1 or 2, invading less than half the muscle wall, with no substantial lymphovascular space invasion, that is classed as low risk and international guidance recommends surgery alone. This is not a compromise or watchful waiting — it is the standard of care, because the risk of recurrence is low enough that treating everyone in that group would expose many women to lasting side effects to benefit very few. For intermediate-risk disease a short course of vaginal vault brachytherapy is usual. Higher-risk features bring pelvic radiation or chemotherapy into the discussion.
Why is the decision only made after the operation?
Because the information needed to make it comes from the specimen. Imaging cannot detect microscopic disease in normal-sized lymph nodes, cannot measure the depth of invasion into the muscle wall precisely, and cannot assess lymphovascular space invasion at all — and that last finding is one of the commonest reasons a woman who expected to need nothing is offered radiation. Grades and stages are also revised in both directions once the whole uterus is examined, and occasionally the histological type is revised too. Any plan discussed before surgery is genuinely provisional, and a team that says so is being accurate rather than evasive.
What is lymphovascular space invasion and why does it matter so much?
It means tumour cells were seen inside the small lymphatic and blood vessels within the wall of the uterus — evidence that the tumour has found a route by which it can travel. It is assessed by the pathologist on the surgical specimen and cannot be established beforehand. Substantial lymphovascular space invasion raises the risk category independently of stage and grade, which is why it is the most frequent explanation for a woman being offered radiation when her stage and grade alone would have suggested none was needed. Reports may distinguish focal from substantial involvement, and that distinction genuinely matters.
Can I decline treatment that has been recommended?
Yes, and where the absolute benefit is small this is a legitimate decision rather than a refusal of care. The useful first step is asking for the numbers in absolute terms: what is my risk of recurrence with this treatment, and what is it without. A treatment that reduces risk from 4 per cent to 2 per cent is described accurately as halving the risk, and whether two percentage points justify several weeks of treatment and lasting effects on bowel, bladder or sexual function is genuinely a matter for you. Age, other health conditions and what you want from the coming year are all reasonable inputs. A good team invites them.
Could molecular testing change what I am offered?
Yes, in either direction, and this is worth confirming before the plan is finalised. A POLE-mutated tumour carries an exceptionally favourable outlook even when it appears high grade, and European guidance supports de-escalating adjuvant treatment in early-stage POLE-mutated disease — one of the few situations in oncology where a test result leads to less treatment. Conversely, a p53-abnormal result places a tumour in the high-risk category regardless of how modest its stage and grade appear. Mismatch repair status matters chiefly if disease recurs, since it predicts response to immunotherapy. All are performed on tissue already removed at surgery.
Medical disclaimer: This page explains how the decision about treatment after surgery for endometrial cancer is made, and is reviewed by a CION oncologist, following current NCCN and ESGO–ESTRO–ESP guidance and the randomised trial evidence underlying it. Risk categories are broad guides rather than rigid rules, and individual recommendations depend on the full surgical pathology. It is general health information rather than advice about your own case, and decisions should be made with the oncology team holding your results.